Main Industry
Biotechnology
Main Product/Service
The company’s lead product, OBI‑858, is a novel 760 kDa botulinum toxin derived from Clostridium botulinum type A. OBI‑858 has successfully completed a Phase I clinical trial, demonstrating excellent safety, tolerability, and preliminary efficacy in reduc
Founded Year
2020
Unified Business No.
82943056
Status
Active
Number of Employees
0
Total Paid-in
Capital
1,069,247,500 (NT$)
Location of Company
Taiwan
, Hsinchu County
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
OBIGEN Pharma, also known as Ding‑Jin Biotech, is the first Taiwan-based company dedicated to the research, development, and manufacturing of its own botulinum toxin products. The company operates under stringent safety and quality standards, maintaining
